{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:18:58Z","timestamp":1790907538598,"version":"4.1.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003768","name":"Universite de Strasbourg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003768","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.clbc.2026.01.003","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T16:47:47Z","timestamp":1767977267000},"page":"93-104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["CDK4\/6 Inhibitors in HER2-positive Metastatic Breast Cancer"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3382-9635","authenticated-orcid":false,"given":"Herv\u00e9","family":"Bischoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Petit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2026.01.003_bib0001","doi-asserted-by":"crossref","first-page":"dju055","DOI":"10.1093\/jnci\/dju055","article-title":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","volume":"106","author":"Howlader","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2026.01.003_bib0002","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3892\/ol.2020.11948","article-title":"Impact of molecular subtypes on metastatic behavior and overall survival in patients with metastatic breast cancer: a single-center study combined with a large cohort study based on the surveillance, epidemiology and end results database","volume":"20","author":"Yang","year":"2020","journal-title":"Oncol Lett"},{"key":"10.1016\/j.clbc.2026.01.003_bib0003","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s10147-022-02115-x","article-title":"The impact of hormone receptor on the clinical outcomes of HER2-positive breast cancer: a population-based study","volume":"27","author":"Han","year":"2022","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.clbc.2026.01.003_bib0004","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","volume":"21","author":"Swain","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2026.01.003_bib0005","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2026.01.003_bib0006","volume":"43","author":"Tolaney","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2026.01.003_bib0007","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1245\/s10434-024-16470-8","article-title":"Immunohistochemical status predicts pathologic complete response to neoadjuvant therapy in HER2-overexpressing breast cancers","volume":"32","author":"Winer","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clbc.2026.01.003_bib0008","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.47154","article-title":"Association of endocrine therapy for HR+\/ERBB2+ metastatic breast cancer with survival outcomes","volume":"5","author":"Carausu","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clbc.2026.01.003_bib0009","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.clbc.2019.02.001","article-title":"ER+\/HER2+ breast cancer has different metastatic patterns and better survival than ER-\/HER2+ breast cancer","volume":"19","author":"Arciero","year":"2019","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clbc.2026.01.003_bib0010","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1073\/pnas.191367098","article-title":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications","volume":"98","author":"S\u00f8rlie","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clbc.2026.01.003_bib0011","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","article-title":"Supervised risk predictor of breast cancer based on intrinsic subtypes","volume":"27","author":"Parker","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2026.01.003_bib0012","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12222","article-title":"A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers","volume":"7","author":"Ferrari","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.clbc.2026.01.003_bib0013","doi-asserted-by":"crossref","first-page":"v603","DOI":"10.1093\/annonc\/mdx391.026","article-title":"Distribution of the PAM50 breast cancer subtypes within each pathology-based group: a combined analysis of 15,339 patients across 29 studies","volume":"28","author":"Cejalvo","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2026.01.003_bib0014","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1158\/1078-0432.CCR-23-1209","article-title":"Overall survival and exploratory biomarker analyses of abemaciclib plus trastuzumab with or without fulvestrant versus Trastuzumab plus chemotherapy in HR+, HER2+ metastatic breast cancer patients","volume":"30","author":"Tolaney","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2026.01.003_bib0015","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10549-022-06629-w","article-title":"Combined analysis of receptor expression reflects inter-and intra-tumor heterogeneity in HR+\/HER2+ breast cancer","volume":"194","author":"Ju","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2026.01.003_bib0016","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.7150\/thno.35730","article-title":"Molecular portraits and trastuzumab responsiveness of estrogen receptor-positive, progesterone receptor-positive, and HER2-positive breast cancer","volume":"9","author":"Zhao","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.clbc.2026.01.003_bib0017","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s11864-024-01252-x","article-title":"Unveiling neoadjuvant therapy: insights and outlooks for HER2-positive early breast cancer","volume":"25","author":"Bischoff","year":"2024","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.clbc.2026.01.003_bib0018","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1200\/JCO.2015.62.1268","article-title":"Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase III trial of paclitaxel plus trastuzumab with or without lapatinib","volume":"34","author":"Carey","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2026.01.003_bib0019","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1470-2045(17)30021-9","article-title":"HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial","volume":"18","author":"Llombart-Cussac","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2026.01.003_bib0020","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS17-P2-09-12","article-title":"Abstract P2-09-12: independent validation of the HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer","volume":"78","author":"Prat","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2026.01.003_bib0021","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS17-PD3-06","article-title":"Abstract PD3-06: association of intrinsic subtypes with pathological complete response (pCR) in the KRISTINE neoadjuvant phase 3 clinical trial in HER2-positive early breast cancer (EBC)","volume":"78","author":"Prat","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2026.01.003_bib0022","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jamaoncol.2023.7304","article-title":"Tumor intrinsic subtypes and gene expression signatures in early-stage ERBB2\/HER2-positive breast cancer: a pooled analysis of CALGB 40601, NeoALTTO, and NSABP B-41 trials","volume":"10","author":"Fernandez-Martinez","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clbc.2026.01.003_bib0023","doi-asserted-by":"crossref","first-page":"865s","DOI":"10.1158\/1078-0432.865s.11.2","article-title":"Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer","volume":"11","author":"Osborne","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2026.01.003_bib0024","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1210\/me.2004-0486","article-title":"Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes","volume":"19","author":"Bj\u00f6rnstr\u00f6m","year":"2005","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.clbc.2026.01.003_bib0025","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/bs.apcsb.2019.01.001","article-title":"Estrogen receptor signaling mechanisms","volume":"116","author":"Fuentes","year":"2019","journal-title":"Adv Protein Chem Struct Biol"},{"key":"10.1016\/j.clbc.2026.01.003_bib0026","first-page":"4429s","article-title":"Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer","volume":"7","author":"Lee","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2026.01.003_bib0027","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/nature07483","article-title":"Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen","volume":"456","author":"Hurtado","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.clbc.2026.01.003_bib0028","first-page":"2435","article-title":"HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells","volume":"10","author":"Pietras","year":"1995","journal-title":"Oncogene"},{"key":"10.1016\/j.clbc.2026.01.003_bib0029","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/jnci\/djh166","article-title":"Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2\/neu cross-talk in ER\/HER2-positive breast cancer","volume":"96","author":"Shou","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2026.01.003_bib0030","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1023\/B:BREA.0000032981.20384.c6","article-title":"Trastuzumab plus tamoxifen: anti-proliferative and molecular interactions in breast carcinoma","volume":"86","author":"Ropero","year":"2004","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2026.01.003_bib0031","doi-asserted-by":"crossref","first-page":"R121","DOI":"10.1186\/bcr3067","article-title":"Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers\u2013role of estrogen receptor and HER2 reactivation","volume":"13","author":"Wang","year":"2011","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.clbc.2026.01.003_bib0032","doi-asserted-by":"crossref","first-page":"8681","DOI":"10.1128\/MCB.24.19.8681-8690.2004","article-title":"Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the her-2\/neu\/phosphatidylinositol 3-kinase\/Akt signaling pathway","volume":"24","author":"Guo","year":"2004","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.clbc.2026.01.003_bib0033","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1038\/sj.bjc.6690196","article-title":"Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer","volume":"79","author":"Houston","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clbc.2026.01.003_bib0034","doi-asserted-by":"crossref","first-page":"5529","DOI":"10.1200\/JCO.2008.20.6847","article-title":"Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study","volume":"27","author":"Kaufman","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2026.01.003_bib0035","doi-asserted-by":"crossref","first-page":"5538","DOI":"10.1200\/JCO.2009.23.3734","article-title":"Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer","volume":"27","author":"Johnston","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2026.01.003_bib0036","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1001\/jamaoncol.2016.0339","article-title":"Effects of estrogen receptor and human epidermal growth factor receptor-2 levels on the efficacy of trastuzumab: a secondary analysis of the HERA trial","volume":"2","author":"Loi","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clbc.2026.01.003_bib0037","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2026.01.003_bib0038","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1038\/onc.2013.137","article-title":"Signaling through cyclin d-dependent kinases","volume":"33","author":"Choi","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.clbc.2026.01.003_bib0039","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1158\/0008-5472.CAN-15-2383","article-title":"HER2 signaling drives DNA anabolism and proliferation through SRC-3 phosphorylation and E2F1-regulated genes","volume":"76","author":"Nikolai","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2026.01.003_bib0040","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1158\/1078-0432.CCR-21-3185","article-title":"Modulation of the estrogen\/erbB2 receptors cross-talk by CDK4\/6 inhibition triggers sustained senescence in estrogen receptor- and ErbB2-positive breast cancer","volume":"28","author":"Vigan\u00f2","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2026.01.003_bib0041","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ccell.2016.02.006","article-title":"Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4\/6 inhibitors","volume":"29","author":"Goel","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clbc.2026.01.003_bib0042","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature23465","article-title":"CDK4\/6 inhibition triggers anti-tumour immunity","volume":"548","author":"Goel","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.clbc.2026.01.003_bib0043","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1200\/JCO.22.00519","article-title":"Systemic therapy for advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO guideline update","volume":"40","author":"Giordano","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2026.01.003_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103756","article-title":"6th and 7th international consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)","volume":"76","author":"Cardoso","year":"2024","journal-title":"Breast"},{"key":"10.1016\/j.clbc.2026.01.003_bib0045","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10549-022-06856-1","article-title":"Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2\u2009+\u2009\/HR\u2009+\u2009metastatic breast cancer","volume":"198","author":"Loft","year":"2023","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2026.01.003_bib0046","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/s41591-024-03021-7","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial","volume":"30","author":"Cort\u00e9s","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.clbc.2026.01.003_bib0047","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2026.01.003_bib0048","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2026.01.003_bib0049","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.annonc.2021.12.005","article-title":"Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis","volume":"33","author":"Curigliano","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2026.01.003_bib0050","doi-asserted-by":"crossref","first-page":"R77","DOI":"10.1186\/bcr2419","article-title":"PD 0332991, a selective cyclin D kinase 4\/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro","volume":"11","author":"Finn","year":"2009","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.clbc.2026.01.003_bib0051","doi-asserted-by":"crossref","first-page":"viii121","DOI":"10.1093\/annonc\/mdy272.357","volume":"29","author":"Loibl","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2026.01.003_bib0052","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1158\/1078-0432.CCR-22-1092","article-title":"Pertuzumab, trastuzumab, and an aromatase inhibitor for HER2-positive and hormone receptor-positive metastatic or locally advanced breast cancer: PERTAIN final analysis","volume":"29","author":"Arpino","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2026.01.003_bib0053","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS22-PD18-07","article-title":"Abstract PD18-07: omission of chemotherapy in the treatment of HER2-positive and hormone-receptor positive metastatic breast cancer \u2013 interim results from the randomized phase 3 DETECT V trial","volume":"83","author":"Janni","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2026.01.003_bib0054","doi-asserted-by":"crossref","first-page":"S362","DOI":"10.1016\/j.annonc.2024.08.298","article-title":"350MO omission of chemotherapy and addition of the CDK4\/6 inhibitor ribociclib in HER2-positive and hormone-receptor positive metastatic breast cancer \u2013 second interim efficacy analysis of the randomized phase III DETECT V trial","volume":"35","author":"Janni","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2026.01.003_bib0055","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1200\/JCO.2025.43.16_suppl.1016","article-title":"Phase IB and II study of ribociclib with trastuzumab plus endocrine therapy in HR+\/HER2+ advanced breast cancer patients: Korean Cancer Study Group BR 18-2 MINI trial","volume":"43","author":"Sohn","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2026.01.003_bib0056","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1158\/1078-0432.CCR-20-0844","article-title":"Palbociclib and Trastuzumab in HER2-positive advanced breast cancer: results from the phase II SOLTI-1303 PATRICIA trial","volume":"26","author":"Ciruelos","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2026.01.003_bib0057","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105572","article-title":"Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial","volume":"10","author":"Pascual","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.clbc.2026.01.003_bib0058","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1200\/JCO.2024.42.16_suppl.1008","article-title":"Primary results from PATRICIA cohort C (SOLTI-1303), a randomized phase II study evaluating palbociclib with trastuzumab and endocrine therapy in pretreated HER2-positive and PAM50 luminal advanced breast cancer","volume":"42","author":"Ciruelos","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2026.01.003_bib0059","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(20)30112-1","article-title":"Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial","volume":"21","author":"Tolaney","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2026.01.003_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104877","article-title":"305MO Phase II trial of TDM-1 and palbociclib in metastatic HER2 positive breast cancer","volume":"10","author":"Chalasani","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.clbc.2026.01.003_bib0061","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S1470-2045(25)00140-8","article-title":"Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a study","volume":"26","author":"Escriv\u00e1-de-Romani","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2026.01.003_bib0062","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.2025.43.16_suppl.1011","article-title":"Circulating tumor DNA (ctDNA) dynamics as a predictor of treatment response in metastatic breast cancer (mBC)","volume":"43","author":"Razavi","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2026.01.003_bib0063","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41523-025-00753-8","article-title":"HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab","volume":"11","author":"S\u00e1nchez-Bayona","year":"2025","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.clbc.2026.01.003_bib0064","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2025.104583","article-title":"Complete responders in patients with HER2-positive metastatic breast cancer: a real-world SONABRE study","volume":"84","author":"Ding","year":"2025","journal-title":"The Breast"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926000030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926000030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T11:48:29Z","timestamp":1779450509000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820926000030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1526820926000030"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2026.01.003","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CDK4\/6 Inhibitors in HER2-positive Metastatic Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2026.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}